Wall Street Zen lowered shares of Scribe Therapeutics (NASDAQ:SCTX – Free Report) from a hold rating to a sell rating in a research note issued to investors on Saturday,Wall Street Zen reports.
Other equities research analysts have also issued research reports about the stock. Leerink Partners assumed coverage on shares of Scribe Therapeutics in a report on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 target price for the company. Wells Fargo & Company initiated coverage on shares of Scribe Therapeutics in a report on Tuesday, August 18th. They set an “overweight” rating and a $60.00 price target on the stock. Zacks Research raised shares of Scribe Therapeutics to a “hold” rating in a research report on Tuesday, September 1st. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Scribe Therapeutics in a research note on Thursday. Finally, Guggenheim started coverage on Scribe Therapeutics in a research report on Tuesday, August 18th. They set a “buy” rating and a $50.00 target price for the company. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Scribe Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $51.75.
Check Out Our Latest Stock Report on Scribe Therapeutics
Scribe Therapeutics Trading Down 8.7%
Scribe Therapeutics (NASDAQ:SCTX – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.26). The company had revenue of $1.64 million during the quarter. On average, research analysts forecast that Scribe Therapeutics will post -4.60 EPS for the current fiscal year.
Institutional Trading of Scribe Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Baker BROS. Advisors LP acquired a new stake in shares of Scribe Therapeutics in the third quarter valued at about $12,675,000. Goldman Sachs Group Inc. acquired a new position in Scribe Therapeutics during the third quarter worth about $398,000. State Street Corp acquired a new position in Scribe Therapeutics during the third quarter worth about $3,150,000. Finally, RA Capital Management L.P. purchased a new stake in Scribe Therapeutics during the 3rd quarter valued at about $33,169,000.
About Scribe Therapeutics
Scribe Therapeutics is a biotechnology company focused on developing CRISPR-based gene-editing technologies and potential genetic medicines. Its platform uses engineered CRISPR systems designed to make targeted changes to DNA, with research aimed at applications across multiple disease areas. Founded in 2017 and based in Alameda, California, the company has pursued research and development collaborations with pharmaceutical companies, including Sanofi and Biogen. Scribe Therapeutics is privately held; I could not verify a Nasdaq listing under the symbol SCTX.
See Also
- Five stocks we like better than Scribe Therapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
